PET imaging of very late antigen-4 in melanoma: Comparison of 68Ga- and 64Cu-Labeled NODAGA and CB-TE1A1P-LLP2A conjugates

Journal of Nuclear Medicine

Volumn 55, Issue 11, 2014, Pages 1856-1863

  Beaino, Wissam ^a   Anderson, Carolyn J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh   (United States)

Author keywords

LLP2A; Melanoma; Metastasis; PET; VLA 4

Indexed keywords

1,4,8,11 TETRAAZACYCLOTETRADECANE 1 (METHANE PHOSPHONIC ACID) 8 (METHANE CARBOXYLIC ACID) PEG4 LLP2A CONJUGATE CU 64; 2 (4,7 BIS(CARBOXYMETHYL) 1,4,7 TRIAZONAN 1 YL)PENTANEDIOIC ACID PEG4 LLP2A CONJUGATE CU 64; 2 (4,7 BIS(CARBOXYMETHYL) 1,4,7 TRIAZONAN 1 YL)PENTANEDIOIC ACID PEG4 LLP2A CONJUGATE GA 68; COPPER 64; GALLIUM 68; LIGAND; LLP2A CONJUGATE; PEPTIDOMIMETIC LIGAND; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; 1,4,8,11-TETRAAZACYCLOTETRADECANE-1-(METHANEPHOSPHONIC ACID)-8-(METHANE CARBOXYLIC ACID); 1-(1,3-CARBOXYPROPYL)-4,7-CARBOXYMETHYL-1,4,7-TRIAZACYCLONONANE; ACETIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; CARBOXYLIC ACID; CHELATING AGENT; COPPER; DIPEPTIDE; FUSED HETEROCYCLIC RINGS; GALLIUM; LLP2A COMPOUND; PEPTIDE; PHOSPHONIC ACID DERIVATIVE; PROTEIN BINDING; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOLUMINESCENCE; C57BL 6 MOUSE; COMPETITIVE BINDING ASSAY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG TUMOR LEVEL; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA CELL; MELANOMA METASTASIS; METASTATIC MELANOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE SYNTHESIS; ANIMAL; BINDING COMPETITION; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; COMPARATIVE STUDY; EXPERIMENTAL MELANOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MELANOMA; METABOLISM; SCINTISCANNING;

ACETATES; ANIMALS; BINDING, COMPETITIVE; CARBOXYLIC ACIDS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; COPPER RADIOISOTOPES; DIPEPTIDES; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HETEROCYCLIC COMPOUNDS, 2-RING; INTEGRIN ALPHA4BETA1; MASS SPECTROMETRY; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ORGANOPHOSPHONATES; PEPTIDES; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING;

EID: 84910593492     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.144881     Document Type: Article

References (25)

1. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg. 1978;135:807-810.
2. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82:364-380.
3. Rose PG. Re: annual report to the nation on the status of cancer (1973 through 1998), featuring cancer with recent increasing trends. J Natl Cancer Inst. 2001;93:1656.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
6. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71:7137-7140.
7. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg. 2002;89:389-396.
8. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oncol Clin N Am. 2007;16:403-430.
9. Ren G, Miao Z, Liu H, et al. Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med. 2009;50:1692-1699.
10. Guo H, Yang J, Shenoy N, Miao Y. Gallium-67-labeled lactam bridge-cyclized a-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging. Bioconjug Chem. 2009;20:2356-2363.
11. Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the avb3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
12. Miyake K, Hasunuma Y, Yagita H, Kimoto M. Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture. J Cell Biol. 1992;119:653-662.
13. Juneja HS, Schmalsteig FC, Lee S, Chen J. Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Exp Hematol. 1993;21:444-450.
14. Holzmann B, Gosslar U, Bittner M. a4 integrins and tumor metastasis. Curr Top Microbiol Immunol. 1998;231:125-141.
15. Hart IR, Birch M, Marshall JF. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev. 1991;10:115-128.
16. Moretti S, Martini L, Berti E, Pinzi C, Giannotti B. Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res. 1993;3:235-239.
17. Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki BM. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst. 1995;87:366-371.
18. Schadendorf D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki BM. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol. 1993;170:429-434.
19. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005;24:195-222.
20. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-Affinity peptidomimetics against a4b1 integrin for in vivo tumor imaging. Nat Chem Biol. 2006;2:381-389.
21. Shokeen M, Zheleznyak A, Wilson JM, et al. Molecular imaging of very late antigen-4 (a4b1 integrin) in the premetastatic niche. J Nucl Med. 2012;53: 779-786.
22. Jiang M, Ferdani R, Shokeen M, Anderson CJ. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors. Nucl Med Biol. 2013;40:245-251.
23. Soodgupta D, Hurchla MA, Jiang M, et al. Very late antigen-4 (a4b1 integrin) targeted PET imaging of multiple myeloma. PLoS ONE. 2013;8:e55841.
24. Hauzenberger D, Klominek J, Holgersson J, Bergstrom SE, Sundqvist KG. Triggering of motile behavior in T lymphocytes via cross-linking of alpha 4 beta 1 and alpha L beta 2. J Immunol. 1997;158:76-84.
25. Klemke M, Weschenfelder T, Konstandin MH, Samstag Y. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol. 2007;212:368-374.